Advanced Cutaneous Squamous Cell Carcinoma in the Era of Systemic Immunotherapy: Implications for Risk Stratification and Treatment
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer after basal cell carcinoma (BCC) (Alam 2018).  The incidence of cSCC in the United States and throughout the world is increasing (Alam 2018).  In the US, each year 200,000-400,000 new cases of cSCC are expected, with d
Category
  • LivDerm
  • TME
Format
  • Webinar recorded
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
CMHC Masterclass On Demand: The Intersection of Cardiometabolic Health and Sleep Disorders
During this Masterclass, expert faculty will discuss the links between sleep disorders and cardiometabolic health, as well as practical approaches for screening, referral, or treatment.
Category
  • CMHC
Format
  • Conference / meeting
  • Video
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
Patient Case: Reducing The Risk for Adverse Events in a T2DM Patient with HFrEF, CKD, and Existing ASCVD
The advent of SGLT-2 inhibitors and GLP-1 RAs to address cardiorenal risk in patients with and without type 2 diabetes, has opened up new avenues of prevention and treatment. However, individualizing the vast amount of evidence to patient care remains challenging.
Category
  • CMHC
Format
  • Self-study / Enduring
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
Virtual Symposium - Bridging the Gap in the Diagnosis and Management of Postmenopausal Osteoporosis
Osteoporosis is a prevalent condition and a major health problem, but particularly more in postmenopausal women. Approximately 2 million osteoporosis-related fractures occur annually in the US, and more than 70% of these occur in women.
Category
  • CMHC
Format
  • Video
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
Navigating the Complexity of PAH: Advances in the Diagnosis and Management – Part II: PAH Treatment - Goals, Therapeutic Options, and Guidelines
Pulmonary arterial hypertension (PAH) is a complex and heterogenous disease, which remains challenging to diagnose and treat.
Category
  • CMHC
Format
  • Video
  • Webinar recorded
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
Navigating the Complexity of PAH: Advances in the Diagnosis and Management – Part I: Screening and Diagnosis of PAH
Pulmonary arterial hypertension (PAH) is a complex and heterogenous disease, which remains challenging to diagnose and treat.
Category
  • CMHC
Format
  • Video
  • Webinar recorded
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
Navigating the Complexity of PAH: Advances in the Diagnosis and Management – Part III: Latest Data on PAH Treatment Approaches
Pulmonary arterial hypertension (PAH) is a complex and heterogenous disease, which remains challenging to diagnose and treat.
Category
  • CMHC
Format
  • Video
  • Webinar recorded
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
Navigating the Complexity of PAH: Advances in the Diagnosis and Management – Part IV: Patient Cases: Putting Evidence Into Perspective
Pulmonary arterial hypertension (PAH) is a complex and heterogenous disease, which remains challenging to diagnose and treat.
Category
  • CMHC
Format
  • Video
  • Webinar recorded
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
The Challenge of Slowing Diabetic Kidney Disease Progression and Reducing Cardiovascular Risk: Recent Advances and Novel Strategies
Diabetic kidney disease (DKD) remains one of the major causes of morbidity and mortality in patients with type 2 diabetes. Despite optimized glycemic control and renin-angiotensin-aldosterone system (RAAS) inhibitor therapy, many patients with DKD progress to kidney failure.
Category
  • CMHC
Format
  • Monograph
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
Virtual Symposium: Antithrombotic Therapy for Symptomatic PAD: Interpreting the Evidence and Recent Advances
Patients with diabetes and PAD, particularly those with concomitant polyvascular disease, are at a greater risk for future adverse cardiovascular and limb events.
Category
  • CMHC
Format
  • Video
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation

Pages